237 related articles for article (PubMed ID: 37487077)
1. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
[TBL] [Abstract][Full Text] [Related]
2. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
3. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
Sato Y; Casson CN; Matsuda A; Kim JI; Shi JQ; Iwasaki S; Chen S; Modrell B; Chan C; Tavares D; Austen D; Ida K; Tayber O; Hein P; Comeau R; Lin Y; Shaw MH
Cancer Immunol Immunother; 2022 Oct; 71(10):2421-2431. PubMed ID: 35237846
[TBL] [Abstract][Full Text] [Related]
4. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
[TBL] [Abstract][Full Text] [Related]
5. An anti-CTLA-4 heavy chain-only antibody with enhanced T
Gan X; Shan Q; Li H; Janssens R; Shen Y; He Y; Chen F; van Haperen R; Drabek D; Li J; Zhang Y; Zhao J; Qin B; Jheng MJ; Chen V; Wang J; Rong Y; Grosveld F
Proc Natl Acad Sci U S A; 2022 Aug; 119(32):e2200879119. PubMed ID: 35925889
[TBL] [Abstract][Full Text] [Related]
6. Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials.
Curtin JF; Candolfi M; Fakhouri TM; Liu C; Alden A; Edwards M; Lowenstein PR; Castro MG
PLoS One; 2008 Apr; 3(4):e1983. PubMed ID: 18431473
[TBL] [Abstract][Full Text] [Related]
7. A Neuropilin-1 Antagonist Exerts Antitumor Immunity by Inhibiting the Suppressive Function of Intratumoral Regulatory T Cells.
Jung K; Kim JA; Kim YJ; Lee HW; Kim CH; Haam S; Kim YS
Cancer Immunol Res; 2020 Jan; 8(1):46-56. PubMed ID: 31554638
[TBL] [Abstract][Full Text] [Related]
8. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
[TBL] [Abstract][Full Text] [Related]
9. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
10. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
11. Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
Tang F; Du X; Liu M; Zheng P; Liu Y
Cell Biosci; 2018; 8():30. PubMed ID: 29713453
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of CTLA-4 and CD47 on T
Zhang A; Ren Z; Tseng KF; Liu X; Li H; Lu C; Cai Y; Minna JD; Fu YX
Sci Transl Med; 2021 Aug; 13(605):. PubMed ID: 34349035
[TBL] [Abstract][Full Text] [Related]
13. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
14. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.
Selby MJ; Engelhardt JJ; Quigley M; Henning KA; Chen T; Srinivasan M; Korman AJ
Cancer Immunol Res; 2013 Jul; 1(1):32-42. PubMed ID: 24777248
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody.
van Elsas MJ; van der Schoot JMS; Bartels A; Steuten K; van Dalen D; Wijfjes Z; Figdor CG; van Hall T; van der Burg SH; Verdoes M; Scheeren FA
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955841
[TBL] [Abstract][Full Text] [Related]
17. Transient Treg depletion enhances therapeutic anti-cancer vaccination.
Fisher SA; Aston WJ; Chee J; Khong A; Cleaver AL; Solin JN; Ma S; Lesterhuis WJ; Dick I; Holt RA; Creaney J; Boon L; Robinson B; Lake RA
Immun Inflamm Dis; 2017 Mar; 5(1):16-28. PubMed ID: 28250921
[TBL] [Abstract][Full Text] [Related]
18. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
[TBL] [Abstract][Full Text] [Related]
19. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.
Sugita S; Keino H; Futagami Y; Takase H; Mochizuki M; Stein-Streilein J; Streilein JW
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5376-84. PubMed ID: 17122127
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment.
Muthana MM; Du X; Liu M; Wang X; Wu W; Ai C; Su L; Zheng P; Liu Y
Elife; 2023 Dec; 12():. PubMed ID: 38127423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
